Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570215 | 0.84 | HDAC3 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26085596 | 0.84 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24158939 | 0.84 | HDAC8 (0.41) | CYP2C9LMNAGAAL3MBTL1MAPT | |
| SCHEMBL21576600 | 0.81 | CYP1A2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2361149 | 0.75 | TDP1 (0.49) | CYP1A2CYP2C19CYP2C9CYP3A4KDM4E | |
| SCHEMBL18092436 | 0.74 | CA1 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9713997 | 0.74 | CYP1A2 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12271793 | 0.73 | KDM4E (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1527205 | 0.73 | SMN1; SMN2 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10940459 | 0.73 | CYP1A2 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3793565-A1 | MCL-1 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112118845-A | MCL-1 inhibitors | 吉利德科学公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.